These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 32408300)

  • 21. EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.
    Schweiger T; Hegedüs B; Nikolowsky C; Hegedüs Z; Szirtes I; Mair R; Birner P; Döme B; Lang G; Klepetko W; Ankersmit HJ; Hoetzenecker K
    Ann Surg Oncol; 2014 Mar; 21(3):946-54. PubMed ID: 24281417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
    Sasaki Y; Hamaguchi T; Yamada Y; Takahashi N; Shoji H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Nagai Y; Taniguchi H; Boku N; Ushijima T; Shimada Y
    Asian Pac J Cancer Prev; 2016; 17(2):539-43. PubMed ID: 26925640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A gene marker panel covering the Wnt and the Ras-Raf-MEK-MAPK signalling pathways allows to detect gene mutations in 80% of early (UICC I) colon cancer stages in humans.
    Scholtka B; Schneider M; Melcher R; Katzenberger T; Friedrich D; Berghof-Jäger K; Scheppach W; Steinberg P
    Cancer Epidemiol; 2009 Aug; 33(2):123-9. PubMed ID: 19679059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features.
    Nazemalhosseini-Mojarad E; Mohammadpour S; Torshizi Esafahani A; Gharib E; Larki P; Moradi A; Amin Porhoseingholi M; Asadzade Aghdaei H; Kuppen PJK; Zali MR
    J Cell Physiol; 2019 Apr; 234(4):4768-4777. PubMed ID: 30370522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
    Aparicio T; Svrcek M; Henriques J; Afchain P; Lièvre A; Tougeron D; Gagniere J; Terrebonne E; Piessen G; Legoux JL; Lecaille C; Pocard M; Gornet JM; Zaanan A; Lavau-Denes S; Lecomte T; Deutsch D; Vernerey D; Puig PL
    Int J Cancer; 2021 Apr; 148(7):1731-1742. PubMed ID: 33186471
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages.
    Li W; Qiu T; Zhi W; Shi S; Zou S; Ling Y; Shan L; Ying J; Lu N
    BMC Cancer; 2015 May; 15():340. PubMed ID: 25929517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MicroRNA-binding site polymorphisms in genes involved in colorectal cancer etiopathogenesis and their impact on disease prognosis.
    Schneiderova M; Naccarati A; Pardini B; Rosa F; Gaetano CD; Jiraskova K; Opattova A; Levy M; Veskrna K; Veskrnova V; Buchler T; Landi S; Vodicka P; Vymetalkova V
    Mutagenesis; 2017 Oct; 32(5):533-542. PubMed ID: 29048575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
    Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
    J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association between mutations of critical pathway genes and survival outcomes according to the tumor location in colorectal cancer.
    Lee DW; Han SW; Cha Y; Bae JM; Kim HP; Lyu J; Han H; Kim H; Jang H; Bang D; Huh I; Park T; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY
    Cancer; 2017 Sep; 123(18):3513-3523. PubMed ID: 28513830
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of novel mutations by exome sequencing in African American colorectal cancer patients.
    Ashktorab H; Daremipouran M; Devaney J; Varma S; Rahi H; Lee E; Shokrani B; Schwartz R; Nickerson ML; Brim H
    Cancer; 2015 Jan; 121(1):34-42. PubMed ID: 25250560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer.
    Jones RP; Sutton PA; Evans JP; Clifford R; McAvoy A; Lewis J; Rousseau A; Mountford R; McWhirter D; Malik HZ
    Br J Cancer; 2017 Mar; 116(7):923-929. PubMed ID: 28208157
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis.
    Zhuang Y; Wang H; Jiang D; Li Y; Feng L; Tian C; Pu M; Wang X; Zhang J; Hu Y; Liu P
    BMC Cancer; 2021 Apr; 21(1):380. PubMed ID: 33836681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. External validation of molecular subtype classifications of colorectal cancer based on microsatellite instability, CIMP, BRAF and KRAS.
    Alwers E; Bläker H; Walter V; Jansen L; Kloor M; Arnold A; Sieber-Frank J; Herpel E; Tagscherer KE; Roth W; Chang-Claude J; Brenner H; Hoffmeister M
    BMC Cancer; 2019 Jul; 19(1):681. PubMed ID: 31296182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High MACC1 expression in combination with mutated KRAS G13 indicates poor survival of colorectal cancer patients.
    Ilm K; Kemmner W; Osterland M; Burock S; Koch G; Herrmann P; Schlag PM; Stein U
    Mol Cancer; 2015 Feb; 14():38. PubMed ID: 25742883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demographic trends and KRAS/BRAF
    Fu X; Huang Y; Fan X; Deng Y; Liu H; Zou H; Wu P; Chen Z; Huang J; Wang J; Lin H; Huang S; Tan X; Lan P; Wang L; Wang JP
    Int J Cancer; 2019 May; 144(9):2109-2117. PubMed ID: 30414169
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports.
    Okada S; Hata K; Kawai K; Yamamoto Y; Tanaka T; Nishikawa T; Sasaki K; Kaneko M; Emoto S; Murono K; Nozawa H
    Medicine (Baltimore); 2019 Mar; 98(12):e14781. PubMed ID: 30896620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy.
    Murcia O; Juárez M; Rodríguez-Soler M; Hernández-Illán E; Giner-Calabuig M; Alustiza M; Egoavil C; Castillejo A; Alenda C; Barberá V; Mangas-Sanjuan C; Yuste A; Bujanda L; Clofent J; Andreu M; Castells A; Llor X; Zapater P; Jover R
    PLoS One; 2018; 13(9):e0203051. PubMed ID: 30188916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.